Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | CTSA | P10619 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10707808 | 0.98 | ALDH1A1 (0.60) | ALDH1A1HPGDLMNAMAOBGRM5 | |
| SCHEMBL24742211 | 0.91 | ALDH1A1 (0.58) | ALDH1A1HPGDLMNAMAOBGRM5 | |
| SCHEMBL29793824 | 0.88 | LMNA (0.62) | ALDH1A1HPGDLMNAMAOBP2RX7 | |
| SCHEMBL18376131 | 0.87 | ALDH1A1 (0.65) | ALDH1A1HPGDLMNAGRM5CTSA | |
| SCHEMBL14371962 | 0.87 | ALDH1A1 (0.65) | ALDH1A1HPGDLMNAGRM5CTSA | |
| SCHEMBL24150763 | 0.86 | ALDH1A1 (0.60) | ALDH1A1HPGDLMNAGRM5CTSA | |
| SCHEMBL10708175 | 0.84 | ALDH1A1 (0.66) | ALDH1A1HPGDLMNAGRM5CTSA | |
| SCHEMBL28948569 | 0.82 | LMNA (0.55) | ALDH1A1HPGDLMNAMAOBP2RX7 | |
| SCHEMBL3024050 | 0.81 | HPGD (0.62) | ALDH1A1HPGDLMNAGRM5CTSA | |
| SCHEMBL2161745 | 0.81 | P2RX7 (0.62) | ALDH1A1HPGDGRM5CTSAP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| US-4764522-A | ANTIDEPRESSANT, ANTIPARKINSON DISEASE | HOFFMANN-LA ROCHE INC. (US) | 1988-08-16 | — | — | US | claimed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2021262596-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20100247543-A1 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| EP-2195029-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | Oryzon Genomics SA (ES) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009027349-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS SA (ES) | 2009-03-05 | — | — | WO | disclosed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-4764522-A | ANTIDEPRESSANT, ANTIPARKINSON DISEASE | HOFFMANN-LA ROCHE INC. (US) | 1988-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | ALDH1A1 2214/4885HPGD 1279/4885LMNA 2523/4885 |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | ALDH1A1 664/4885HPGD 1525/4885LMNA 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.